This Website uses cookies in order to offer you the most relevant experience. Please accept cookies for optimal performance.

Investor Relations Download Info Pack
Why Cordlife
Why Cordlife

Cordlife's Cord Blood Release Track Record

Total Releases: 56

Autologous: 36

Allogeneic: 20

Cerebral Palsy: 19

Thalassaemia Major: 11

Autism Spectrum Disorder (ASD): 9

Leukaemia: 8

Neuroblastoma: 3

Brain Injury: 2

Hypoxic-Ischemic Encephalopathy: 2

Fanconi Anaemia: 1

Global Development Delay: 1



The table below features the cord blood releases performed by Cordlife Group Limited and its subsidiaries. As a Group, Cordlife has made cord blood releases, all of which have been used successfully in transplants or cellular therapy. This is the ultimate validation of our cord blood processing and storage capability.

NO RELEASE MEDICAL CONDITION RECIPIENT'S RELATIONSHIP STORAGE TIME (in months) TREATMENT FACILITY
Show all
Cord blood units sent to South Korea were used for two separate infusions for two children (twins). Some releases may be for the same client but released in different period. This list shows the cord blood released by Cordlife and subsidiaries to support the treatment of various diseases. This should not be used as a reference for the list of treatable diseases by cord blood stem cells. In addition, banking your baby’s cord blood does not guarantee that the stem cells will provide a cure or be applicable for every situation. The use is ultimately determined by the treating physician.

DCR No. 3911, Version G, November 2019
X            

Want to discover the power of umbilical cord stem cells?

Call us at 6238 0808 or make an appointment for a non-obligatory consultation!
Make an appointment